NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
National Cancer Institute (NCI)
I-Mab Biopharma US Limited
Merck Sharp & Dohme LLC
Pfizer
Incyte Corporation
Numab Therapeutics AG
Stanford University
Sellas Life Sciences Group
ADC Therapeutics S.A.
Eli Lilly and Company
Genmab
AstraZeneca
Corcept Therapeutics
Tesaro, Inc.
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Duke University
Incyte Corporation
Eli Lilly and Company
Gilead Sciences
Novartis
Incyte Corporation
Pfizer
Ipsen